What DNA Electronics does

DNA Electronics (DNAe) is a molecular diagnostics company founded in 2003 as a spin-out from Imperial College London, developing the LiDia-SEQ platform — described as the world's first fully automated, sample-to-report next-generation sequencing (NGS) diagnostic system. The platform is built on proprietary semiconductor sequencing technology invented by co-founder Professor Christofer Toumazou, which detects protons released during DNA synthesis on a silicon-chip based transistor, enabling an optics-free, label-free, compact benchtop device operable by non-specialist users at the point-of-need. The flagship assay is a bloodstream infection and antimicrobial resistance (BSI/AMR) test that delivers pathogen identification directly from whole blood in approximately 3-4 hours, compared to 2-6 days for traditional blood culture, covering roughly 7,400 bacterial species, ~800 fungal species, and 26 AMR markers. A development pipeline extends the platform into oncology (circulating tumor DNA liquid biopsy, including a Specific Variant Capture method) and viral detection.

DNAe operates a platform-plus-consumables revenue model: the LiDia-SEQ instrument is sold or leased to hospitals, STAT labs, and clinical facilities, with recurring revenue from proprietary test cartridges and accompanying software that produces diagnostic reports. The go-to-market is enterprise field sales targeting large hospital systems and academic medical centers, supported by an Early Access Program (launched December 2025) and presence at major scientific conferences. The company is pre-commercial — initial commercial launch is targeted for early 2027 in North America and the UK for research use only, with phased European rollout followed by expansion into Asia and the Middle East. Revenue is not disclosed; the company has been funded primarily through a BARDA contract worth up to $51.9 million (awarded September 2016) and is backed by Genting Berhad as a major shareholder. The LiDia-SEQ system and BSI/AMR test received FDA Breakthrough Device designation in April 2020.

Name

DNA Electronics

Legal name

DNAe Group Holdings Limited

Website

https://dnae.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

101–250 employees

Short description

DNA Electronics (DNAe) is a pre-commercial molecular diagnostics company developing the LiDia-SEQ platform, a fully automated semiconductor NGS system enabling rapid point-of-need pathogen and oncology testing for hospitals and clinical laboratories.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

akta.pro secondary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

Keywords

• Semiconductor sequencing diagnostics
• Molecular diagnostics platform
• Bloodstream infection testing
• Antimicrobial resistance diagnostics
• Point-of-care genomics

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Diagnostic Platform (LiDia-SEQ System) Sales/Leasing: DNAe generates revenue from the sale or leasing of its LiDia-SEQ benchtop sequencing system/devices to hospitals, STAT labs, and clinical facilities. The system is a desktop device deployable at the point-of-need, operated by non-technical staff.
2. Diagnostic Test Kits (Consumables): Revenue is generated from the sale of proprietary test kits (consumable cartridges) used with the LiDia-SEQ platform. Tests include the BSI/AMR test, oncology/cancer monitoring tests, and a growing pipeline of follow-on tests. The platform consists of the system, test kits, and software.
3. Software / Diagnostic Reporting: Revenue is generated from the software component of the LiDia-SEQ platform which provides clinically actionable diagnostic reports output to clinicians, as part of the integrated platform offering.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

DNAe develops and manufactures the LiDia-SEQ Platform, a benchtop DNA sequencing system that performs rapid, fully automated next-generation sequencing on disposable semiconductor microchip cartridges. Its first commercial assay is the BSI/AMR Test, designed to identify bloodstream infections and antimicrobial resistance markers directly from whole blood in approximately three to four hours, intended for use in hospital and clinical laboratory settings without requiring specialist molecular biology expertise.

Product overview

DNA Electronics (DNAe) is developing the LiDia-SEQ™ Platform as its core product — a direct-from-specimen, fully automated semiconductor sequencing diagnostic system that performs DNA sequencing on a microchip to deliver rapid, actionable genomic information at the point-of-need. The platform hosts multiple tests including the BSI/AMR Test (the first commercially targeted assay for bloodstream infections and antimicrobial resistance detection from whole blood in 3-4 hours), oncology/cancer tests using liquid biopsy and circulating tumor DNA (ctDNA) analysis, and viral detection tests in the pipeline. The portfolio also includes the proprietary Specific Variant Capture (SVC) method for ctDNA enrichment. This represents a unified platform-plus-tests architecture where the LiDia-SEQ™ system and test kits work together to provide sample-to-result diagnostics across infectious disease and oncology applications.

Differentiator

Problem solved

Functional benefit

Brands

• LiDia-SEQ™: Direct-from-specimen diagnostic system that performs DNA sequencing on a microchip, providing rapid, actionable information to clinicians. The world's first fully automated NGS-based diagnostic platform for bloodstream infections, oncology, and antimicrobial resistance detection.

Products and services

• LiDia-SEQ Platform

Quantifiable outcome

• Results delivered in 3-4 hours vs. 2-6 days for traditional blood culture testing
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered significant, core and supporting.

• University of LeicestersignificantStrategic or Co-development Partner · 27 October 2021DNAe, Imperial College London, and the University of Leicester were awarded a UK Knowledge Transfer Partnership (KTP) by Innovate UK to develop an NGS-based liquid biopsy test for early detection of recurrent breast cancer. Professor Jacqui Shaw from Leicester contributes expertise in circulating tumor DNA and translational cancer genetics.
• Imperial College LondoncoreStrategic or Co-development PartnerDNAe was founded as a spin-out from Imperial College London in 2003 by Regius Professor Christofer Toumazou. Professor Toumazou remains Executive Chairman and Founder. DNAe relocated its UK headquarters to Scale Space, a partnership between Imperial College London and Blenheim Chalcot. The company maintains ongoing research partnerships with Imperial faculty.
• Professor Charles Coombes (Imperial College London)significantStrategic or Co-development PartnerProfessor Charles Coombes, Professor of Medical Oncology at Imperial College London and Honorary Consultant Medical Oncologist, leads the academic side of the KTP collaboration on breast cancer liquid biopsy testing. His research in using circulating tumor DNA to manage breast cancer treatment is being integrated into DNAe's diagnostic platform.
• Scale Space (Imperial College London / Blenheim Chalcot Joint Venture)supportingStrategic or Co-development PartnerDNAe relocated its UK operations to Scale Space in 2019/2020 — a partnership between Imperial College London and Blenheim Chalcot. Scale Space provides office and laboratory facilities near the White City innovation hub.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Cepheid (Danaher): GeneXpert systems are the dominant rapid molecular diagnostics platform in hospitals globally, including for BSI-related applications; large installed base, menu breadth, and hospital workflow integration make Cepheid a primary reference competitor for DNAe's commercialization.
• Oxford Nanopore Technologies: Pioneered a fundamentally novel, non-optical NGS architecture (nanopore-based detection of DNA); while chemistry differs, both Oxford Nanopore and DNAe share the strategic positioning of alternative-architecture sequencing platforms competing with optical/Illumina-style NGS in infectious disease and oncology use cases.
• bioMérieux (BioFire FilmArray): BioFire FilmArray Blood Culture Identification panels and broader syndromic molecular diagnostics franchise target the same hospital microbiology customers and rapid ID/AST workflows that LiDia-SEQ's BSI/AMR assay addresses.
• QIAGEN (QIAstat-Dx): QIAstat-Dx is a cartridge-based, sample-to-result real-time PCR syndromic diagnostics system targeting hospital point-of-need infectious disease testing, closely comparable to DNAe's benchtop, cartridge-contained automated approach and target customer.
• Accelerate Diagnostics: Accelerate Pheno system provides rapid identification and antimicrobial susceptibility testing directly from positive blood cultures — addressing the same BSI/AMR clinical decision-point and competing for the same hospital microbiology budgets as DNAe's LiDia-SEQ.
• GenMark Diagnostics (Roche): ePlex and other cartridge-based molecular diagnostic systems targeting hospital syndromic and infectious-disease testing; comparable benchtop, cartridge-platform business model and customer base to DNAe's LiDia-SEQ (now part of Roche).
• T2 Biosystems: Direct competitor in rapid molecular diagnostics for bloodstream infections and sepsis; T2Bacteria and T2Candida panels deliver species ID directly from whole blood without blood culture, making T2 the most head-to-head comp to DNAe's BSI/AMR test.

Broad incumbents

• Illumina: Dominant NGS incumbent whose benchtop (NextSeq, iSeq) and larger instruments, reagents, and IVD partnerships underpin most clinical sequencing workflows; relevant as the broader competitive backdrop and potential partner for DNAe's oncology applications.
• Pacific Biosciences: Long-read NGS platform (HiFi sequencing via SMRT technology); relevant as another alternative-architecture sequencing competitor and as a comparable benchtop sequencing-platform company with infectious-disease and oncology ambitions.

Emerging players

• Karius: Cell-free DNA-based infectious disease diagnostics (Karius Test) for rapid pathogen identification from blood, including for immunocompromised and sepsis patients; a smaller commercial-stage emerging player addressing the same clinical use case from a different technological angle.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/dna_electronics
• LinkedInlinkedin.com/company/dna-electronics/mycompany/verification/?viewAsMember=true
• Instagraminstagram.com/dna.electronics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DNA Electronics